or Try an Advanced Search...

    Technical Analysis for RCE - Recce Ltd  

    Grade Last Price % Change Price Change
    A 0.635 -5.22% -0.035
    RCE closed down 5.22 percent on Monday, April 29, 2024, on 33 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical RCE trend table...
    Date Alert Name Type % Chg
    Upper Bollinger Band Walk Strength 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Upper Bollinger Band Walk Strength -5.22%
    Wide Bands Range Expansion -5.22%
    Above Upper BB Strength -5.22%
    Overbought Stochastic Strength -5.22%
    Expansion Breakout Bullish Swing Setup -7.30%
    Pocket Pivot Bullish Swing Setup -7.30%
    Older End-of-Day Signals for RCE ...

       Recent Intraday Alerts

    Alert Time
    Down 1 ATR about 13 hours ago
    Down 5% about 13 hours ago
    Down 3% about 14 hours ago
    Fell Below Previous Day's Low about 17 hours ago
    Down 2% about 17 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    RCE Chart by TradingView
    Basic chart:

    Profile

    Recce Ltd   Description

    Recce Limited is an Australia-based research-based pharmaceutical company. The Company is principally engaged in research and development of antibiotic drugs and anticancer drugs. The Company's antibiotics kill both susceptible bacteria and drug resistant super bugs throughout the world health danger arising from resistance to present-day antibiotics. The Company offers antibiotic drugs to treat the diseases caused by Sepsis, Helicobacter Pylori (H.Pylori), Escherichia coli (E.coli), Gonorrhea and Tuberculosis (TB). The Company offers anticancer drugs to treat various cancers, such as leukemia, prostate, lung, stomach, intestine, kidney and melanoma. The Company also offers polymer-antibiotics targeted for human use. The Company's Recce antibiotic kills all types of bacteria, including superbugs. Its subsidiaries include Recce (USA) LLP and Recce (UK) Limited.

    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Major
    Keywords: Health Medicine Pharmaceutical Disease Cancer Diseases Drugs Cancers Resistance Pharmaceuticals Policy Bacteria Bacteriology Antibiotic Chemotherapy Antibiotics Leukemia Melanoma Stomach Veterinary Medicine

    Is RCE a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 17 Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)
    Apr 10 Recce Pharmaceuticals Provides Business Update
    Apr 10 Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024
    Apr 4 Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives
    Mar 22 Recce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP Portfolio
    Mar 19 Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
    Mar 14 Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
    Mar 13 Recce Pharmaceuticals to Present at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting
    Mar 12 Recce Pharmaceuticals Receives AUD $11.17 Million Research and Development (R&D) Advance
    Feb 29 Recce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research Institute
    See more RCE news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 0.785
    52 Week Low 0.41
    Average Volume 184,952
    200-Day Moving Average 0.519
    50-Day Moving Average 0.478
    20-Day Moving Average 0.518
    10-Day Moving Average 0.577
    Average True Range 0.032
    RSI (14) 68.45
    ADX 40.78
    +DI 46.522
    -DI 14.161
    Chandelier Exit (Long, 3 ATRs) 0.599
    Chandelier Exit (Short, 3 ATRs) 0.526
    Upper Bollinger Bands 0.667
    Lower Bollinger Band 0.369
    Percent B (%b) 0.89
    BandWidth 57.590
    MACD Line 0.048
    MACD Signal Line 0.030
    MACD Histogram 0.0176
    Fundamentals Value
    Market Cap 110.26 Million
    Num Shares 174 Million
    EPS -0.03
    Price-to-Earnings (P/E) Ratio -21.17
    Price-to-Sales 0.00
    Price-to-Book 81.46
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.688
    Resistance 3 (R3) 0.693 0.682 0.679
    Resistance 2 (R2) 0.682 0.668 0.679 0.676
    Resistance 1 (R1) 0.658 0.660 0.653 0.653 0.673
    Pivot Point 0.647 0.647 0.644 0.644 0.647
    Support 1 (S1) 0.623 0.633 0.618 0.618 0.597
    Support 2 (S2) 0.612 0.625 0.609 0.594
    Support 3 (S3) 0.588 0.612 0.591
    Support 4 (S4) 0.583